Price
$7.90
Increased by +2.60%
Dollar volume (20D)
19.89 M
ADR%
1.03
Earnings report date
Jun 12, 2024
Shares float
47.88 M
Shares short
3.89 M [8.12%]
Shares outstanding
68.60 M
Market cap
4.46 B
Beta
0.97
Price/earnings
N/A
20D range
7.50 64.97
50D range
7.50 64.97
200D range
7.50 64.97

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company.

It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases.

The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.

It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias.

The company was incorporated in 2007 and is headquartered in Seattle, Washington.

As of May 20, 2024, Alpine Immune Sciences, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Jun 12, 24 -0.28
Increased by 0.00%
-0.41
Increased by +31.71%
Mar 18, 24 0.12
Increased by +129.27%
-0.34
Increased by +135.29%
Nov 14, 23 -0.24
Increased by +42.86%
-0.33
Increased by +27.27%
Aug 14, 23 -0.27
Increased by +55.00%
-0.37
Increased by +27.03%
May 11, 23 -0.28
Decreased by -12.00%
-0.37
Increased by +24.32%
Mar 23, 23 -0.41
Increased by +21.15%
-0.27
Decreased by -51.85%
Nov 14, 22 -0.42
Increased by +23.64%
-0.10
Decreased by -320.00%
Aug 11, 22 -0.60
Decreased by -30.43%
-0.39
Decreased by -53.85%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 24 7.03 M
Decreased by -25.09%
-17.92 M
Decreased by -62.74%
Decreased by -254.81%
Decreased by -117.25%
Dec 31, 23 30.85 M
Increased by +1.01 K%
5.96 M
Increased by +131.59%
Increased by +19.32%
Increased by +102.84%
Sep 30, 23 10.04 M
Increased by +20.03%
-11.72 M
Increased by +7.80%
Decreased by -116.72%
Increased by +23.19%
Jun 30, 23 8.59 M
Increased by +62.38%
-13.16 M
Increased by +27.31%
Decreased by -153.10%
Increased by +55.23%
Mar 31, 23 9.39 M
Decreased by -31.12%
-11.01 M
Decreased by -46.27%
Decreased by -117.29%
Decreased by -112.37%
Dec 31, 22 2.78 M
Decreased by -38.72%
-18.86 M
Decreased by -24.38%
Decreased by -679.54%
Decreased by -102.96%
Sep 30, 22 8.37 M
Decreased by -1.75%
-12.71 M
Increased by +5.78%
Decreased by -151.95%
Increased by +4.10%
Jun 30, 22 5.29 M
Decreased by -26.43%
-18.10 M
Decreased by -64.09%
Decreased by -341.99%
Decreased by -123.04%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY